Filing Flows › Entrada Therapeutics (TRDA) › How it makes money
How Entrada Therapeutics (TRDA) makes money
Entrada Therapeutics (TRDA) made $905K of revenue in the third quarter 2026 (Q3 2026), -44% from a year earlier.
Drawing the Sankey…
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $905K | 100.0% |
| Income tax | $27K | 3.0% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $905K | -44% |
| Q2 2026 | $898K | -54% |
| Q1 2026 | $875K | -96% |
| Q4 2025 | $1.3M | -96% |
| Q3 2025 | $1.6M | -92% |
| Q2 2025 | $1.9M | -98% |
| Q1 2025 | $20.6M | -65% |
From Entrada Therapeutics' 10-Q filed Nov 5, 2026 (on EDGAR).
Questions
How does Entrada Therapeutics make money?
Entrada Therapeutics (TRDA) made $905K of revenue in the third quarter 2026 (Q3 2026), -44% from a year earlier.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.